64
Participants
Start Date
September 10, 2024
Primary Completion Date
September 10, 2025
Study Completion Date
April 8, 2026
ART5803
A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.
Nucleus Network Pty Ltd, Melbourne
Lead Sponsor
Arialys Therapeutics
INDUSTRY